Frankfurt-based medical cannabis research and development startup Farmako has secured a seven-figure seed funding from German health tech platform Heartbeat Labs. Cannabis owns an immense therapeutic aspect of chronic pain management. Since the early 20th century, the research of weed products remained to be banned or constrained due to governmental policies across the globe. The funding will boost up Farmako for its mission to replenish the research of remedial benefits of cannabis keeping the wellbeing of millions of patients worldwide in mind.
Founder and CEO of Heartbeat Labs, Eckhardt Weber expressed, “The market for alternative medicines is a very relevant and rapidly growing area of pharmaceutical healthcare. Farmako complements our portfolio and we’re continuing to establish Heartbeat Labs as the leading platform for modernizing the healthcare sector.”